共 239 条
[31]
Schleifman E(2019)Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial Ann. Oncol. 30 281-588
[32]
Zou W(2018)Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression J. Clin. Invest. 128 805-2426
[33]
Li Y(2018)PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression J. Clin. Invest. 128 580-10126
[34]
Hellmann MD(2017)First-line nivolumab in stage iv or recurrent non-small-cell lung cancer N. Engl. J. Med. 376 2415-691
[35]
Ciuleanu TE(2018)Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) Proc. Natl Acad. Sci. USA 115 10119-538
[36]
Pluzanski A(2017)Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples Clin. Lung Cancer 18 682-153
[37]
Lee JS(2017)Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy Mod. Pathol. 30 530-708
[38]
Otterson GA(2016)Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies Ann. Oncol. 27 147-148
[39]
Audigier-Valette C(2018)Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non-small cell lung carcinomas Appl. Immunohistochem. Mol. Morphol. 26 701-615
[40]
Garon EB(2012)Impact of collection and storage of lung tumor tissue on whole genome expression profiling J. Mol. Diagn. 14 140-1331